SynthesisCardiovascular and interventional radiology2026
Percutaneous Sclerotherapy of Postoperative Lymphoceles: A Systematic Review and Meta-analysis of Different Sclerosant Agents.
Synthesis in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to provide a meta-analysis of relevant outcomes related to various sclerosant agents used in percutaneous lymphocele sclerotherapy. MATERIALS AND
methodsA systematic review, registered on PROSPERO (Record CRD420251180687), was performed using PubMed, Scopus, and Web of Science, including studies reporting any kind of postoperative lymphoceles treated with a sclerosant agent. Searches were updated to November 2025. Pooled success, recurrence, and complication rates were estimated for each sclerosant agent, and differences across agents were explored. The risk of bias was assessed using Methodological Index for Non-Randomized Studies, while the certainty of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation.
resultsSixteen studies were included-fifteen retrospective and one prospective-reporting on different sclerosant agents: ethanol, povidone-iodine, OK-432, fibrin glue, polidocanol, and doxycycline. A total of 335 lymphoceles were studied. Ethanol showed the most consistent results, with high clinical success (97.4%, 95% CI 82.6-99.7%) and low recurrence rates across the studies (6.7%, 95% CI 3.1-14.2%). The other sclerosant agents yielded similar results but with a lower grade of evidence certainty. Minor complication rates were low (12.2%), consisting predominantly of mild and self-limiting adverse events; only two major complications were reported. Limitations were heterogeneity among studies and predominance of retrospective designs.
conclusionsPercutaneous sclerotherapy yielded favorable results with all agents; however, ethanol is the best-characterized agent, with consistent outcomes and moderate certainty of evidence. High-quality, prospective research is needed in order to choose the best sclerosant agent and standardize the procedure. LEVEL OF EVIDENCE: Level IV, systematic review of retrospective non-comparative studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.